Statins were demonstrated to reduce VEGF expression or serum VEGF levels in a variety of diseases with increased VEGF expression such as type 2 diabetes, coronary artery disease, dyslipidemia, and lung cancer, and their use has been encouraged for their pleiotropic and antiangiogenic effects (17–19). This evidence concerns the gene VEGFA and lung carcinoma.